Melatonin attenuates antipsychotic metabolic effects: An eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial

Bipolar Disorders

Volumn 16, Issue 4, 2014, Pages 410-421

  Romo Nava, Francisco ^a,b,c   Alvarez Icaza González, Dení ^b   Fresán Orellana, Ana ^b   Saracco Alvarez, Ricardo ^b   Becerra Palars, Claudia ^b   Moreno, Julia ^b   Ontiveros Uribe, Martha P ^b   Berlanga, Carlos ^b   Heinze, Gerhard ^a   Buijs, Ruud M ^c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b Clínica de Esquizofrenia Instituto Nacional de Psiquiatría Dr Ramón de la Fuente   (Mexico)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

Author keywords

Bipolar disorder; Blood pressure; Fat mass; Melatonin; Metabolic; Schizophrenia; Second generation antipsychotic; Weight

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; CRONOCAPS; GLUCOSE; LAMOTRIGINE; LITHIUM; MELATONIN; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VALPROIC ACID; ANTIOXIDANT;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BIPOLAR DISORDER; BLOOD PRESSURE; BODY COMPOSITION; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FAT MASS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MALE; METABOLIC BALANCE; METABOLIC DISORDER; METABOLIC SYNDROME X; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SUPRACHIASMATIC NUCLEUS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ANALYSIS OF VARIANCE; ANTHROPOMETRY; COMPLICATION; MENTAL DISORDERS; METABOLIC DISEASES; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; ANALYSIS OF VARIANCE; ANTHROPOMETRY; ANTIOXIDANTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELATONIN; MENTAL DISORDERS; METABOLIC DISEASES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84901913865     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12196     Document Type: Article

References (56)

1. Bowie CR, Depp C, McGrath JA et al. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am J Psychiatry 2010; 167: 1116-1124.
2. Vancampfort D, Vansteelandt K, Correll CU et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013; 170: 265-274.
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-564.
4. Yatham LN, Kennedy SH, Parikh SV et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013; 15: 1-44.
5. Gaebel W, Weinmann S, Sartorius N, Kissling W. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 2005; 187: 248-255.
6. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
7. Kilbourne AM, Brar JS, Drayer RA, Xu X, Post EP. Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Psychosomatics 2007; 48: 412-417.
8. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997; 171: 502-508.
9. Garcia-Portilla MP, Saiz PA, Bascaran MT et al. Cardiovascular risk in patients with bipolar disorder. J Affect Disord 2009; 115: 302-308.
10. Girgis RR, Javitch JA, Lieberman JA. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry 2008; 13: 918-929.
11. Rasmussen DD, Boldt BM, Wilkinson CW, Yellon SM, Matsumoto AM. Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. Endocrinology 1999; 140: 1009-1012.
12. Wolden-Hanson T, Mitton DR, McCants RL et al. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 2000; 141: 487-497.
13. Terron MP, Delgado-Adamez J, Pariente JA, Barriga C, Paredes SD, Rodriguez AB. Melatonin reduces body weight gain and increases nocturnal activity in male Wistar rats. Physiol Behav 2013; 118: 8-13.
14. Raskind MA, Burke BL, Citres NJ, Tapp AM, Rasmussen DD. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology 2007; 32: 284-288.
15. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: nature's most versatile biological signal? FEBS J 2006; 273: 2813-2838.
16. Reppert SM. Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms 1997; 12: 528-531.
17. Wyatt JK, Dijk DJ, Ritz-de Cecco A, Ronda JM, Czeisler CA. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep 2006; 29: 609-618.
18. Laposky AD, Bass J, Kohsaka A, Turek FW. Sleep and circadian rhythms: key components in the regulation of energy metabolism. FEBS Lett 2008; 582: 142-151.
19. Scheer F. Daily night time melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004; 43: 192-197.
20. Kozirog M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res 2011; 50: 261-266.
21. Srinivasan V, Smits M, Spence W et al. Melatonin in mood disorders. World J Biol Psychiatry 2006; 7: 138-151.
22. Nduhirabandi F, Du Toit EF, Blackhurst D, Marais D, Lochner A. Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. J Pineal Res 2011; 50: 171-182.
23. Espino J, Pariente JA, Rodriguez AB. Role of melatonin on diabetes-related metabolic disorders. World J Diabetes 2011; 2: 82-91.
24. Kay S, Fiszbein A, Vital-Herne M, Fuentes L. The Positive and Negative Syndrome Scale - Spanish adaptation. J Nerv Ment Dis 1990; 178: 510-517.
25. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976.
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
27. Apiquian R. Validez y confiabilidad de la escala para la evaluación de la Manía. Salud Ment 1997; 20: 23-29.
28. Addington D, Addington J, Atkinson M. A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Schizophr Res 1996; 19: 205-212.
29. Wulff K, Gatti S, Wettstein JG, Foster RG. Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. Nat Rev Neurosci 2010; 11: 589-599.
30. Wulff K, Dijk DJ, Middleton B, Foster RG, Joyce EM. Sleep and circadian rhythm disruption in schizophrenia. Br J Psychiatry 2012; 200: 308-316.
31. Murray G, Harvey A. Circadian rhythms and sleep in bipolar disorder. Bipolar Disord 2010; 12: 459-472.
32. Guan N, Liu H, Diao F, Zhang J, Zhang M, Wu T. Prevalence of metabolic syndrome in bipolar patients initiating acute-phase treatment: a 6-month follow up. Psychiatry Clin Neurosci 2010; 64: 625-633.
33. Ritter PS, Marx C, Lewtschenko N et al. The characteristics of sleep in patients with manifest bipolar disorder, subjects at high risk of developing the disease and healthy controls. J Neural Transm 2012; 119: 1173-1184.
34. Forest G, Poulin J, Daoust AM, Lussier I, Stip E, Godbout R. Attention and non-REM sleep in neuroleptic-naive persons with schizophrenia and control participants. Psychiatry Res 2007; 149: 33-40.
35. Wu YH, Ursinus J, Zhou JN et al. Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression. J Affect Disord 2013; 148: 357-367.
36. Weston-Green K, Huang XF, Deng C. Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. PLoS ONE 2012; 7: e33548.
37. Kiss A, Bundzikova J, Pirnik Z, Mikkelsen JD. Different antipsychotics elicit different effects on magnocellular oxytocinergic and vasopressinergic neurons as revealed by Fos immunohistochemistry. J Neurosci Res 2010; 88: 677-685.
38. Buijs RM, Scheer FA, Kreier F et al. Organization of circadian functions: interaction with the body. Prog Brain Res 2006; 153: 341-360.
39. Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994; 13: 1177-1185.
40. Liu C, Weaver DR, Jin X et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997; 19: 91-102.
41. van den Top M, Buijs RM, Ruijter JM, Delagrange P, Spanswick D, Hermes ML. Melatonin generates an outward potassium current in rat suprachiasmatic nucleus neurones in vitro independent of their circadian rhythm. Neuroscience 2001; 107: 99-108.
42. Kreier F, Fliers E, Voshol PJ et al. Selective parasympathetic innervation of subcutaneous and intra-abdominal fat-functional implications. J Clin Invest 2002; 110: 1243-1250.
43. Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag 2011; 7: 577-584.
44. Cardinali DP, Cano P, Jimenez-Ortega V, Esquifino AI. Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications. Neuroendocrinology 2011; 93: 133-142.
45. Kadhim HM, Ismail SH, Hussein KI et al. Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin. J Pineal Res 2006; 41: 189-193.
46. Lusardi P, Preti P, Savino S, Piazza E, Zoppi A, Fogari R. Effect of bedtime melatonin ingestion on blood pressure of normotensive subjects. Blood Press Monit 1997; 2: 99-103.
47. Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis 2012; 27: 113-119.
48. Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry 2004; 65: 686-689.
49. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92-100.
50. Puchalski SS, Green JN, Rasmussen DD. Melatonin effect on rat body weight regulation in response to high-fat diet at middle age. Endocrine 2003; 21: 163-167.
51. Bartness TJ, Wade GN. Photoperiodic control of seasonal body weight cycles in hamsters. Neurosci Biobehav Rev 1985; 9: 599-612.
52. Chengappa KN, Chalasani L, Brar JS, Parepally H, Houck P, Levine J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin Ther 2002; 24: 1576-1584.
53. Aichhorn W, Marksteiner J, Walch T, Zernig G, Saria A, Kemmler G. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 2006; 21: 81-85.
54. Dokucu ME, Yu L, Taghert PH. Lithium- and valproate-induced alterations in circadian locomotor behavior in Drosophila. Neuropsychopharmacology 2005; 30: 2216-2224.
55. Iwahana E, Akiyama M, Miyakawa K et al. Effect of lithium on the circadian rhythms of locomotor activity and glycogen synthase kinase-3 protein expression in the mouse suprachiasmatic nuclei. Eur J Neurosci 2004; 19: 2281-2287.
56. Abe M, Herzog ED, Block GD. Lithium lengthens the circadian period of individual suprachiasmatic nucleus neurons. Neuroreport 2000; 11: 3261-3264.